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REVIEW
The Evaluation of Rectal Bleeding in Adults
A Cost-effectiveness Analysis Comparing Four Diagnostic Strategies

Elizabeth Allen, MD,1 Christina Nicolaidis, MD, MPH,2 Mark Helfand, MD, MPH1
1

Portland Veterans Affairs Medical Center, Portland, OR, USA; 2Oregon Health & Science University, Portland, OR, USA.

BACKGROUND: Though primary care patients commonly present with
rectal bleeding, the optimal evaluation strategy remains unknown.
OBJECTIVE: To compare the cost-effectiveness of four diagnostic
strategies in the evaluation of rectal bleeding.
DESIGN: Cost-effectiveness analysis using a Markov decision model.
DATA SOURCES: Systematic review of the literature, Medicare reimbursement data, Surveillance, Epidemiology, and End Results (SEER)
Cancer Registry.
TARGET POPULATION: Patients over age 40 with otherwise asymptomatic rectal bleeding.
TIME HORIZON: The patient’s lifetime.
PERSPECTIVE: Modified societal perspective.
INTERVENTIONS: Watchful waiting, flexible sigmoidoscopy, flexible
sigmoidoscopy followed by air contrast barium enema (FS1ACBE),
and colonoscopy.
OUTCOME MEASURES: Incremental cost-effectiveness ratio.
RESULTS OF BASE-CASE ANALYSIS: The incremental cost-effectiveness ratio for colonoscopy compared with flexible sigmoidoscopy was
$5,480 per quality-adjusted year of life saved (QALY). Watchful waiting
and FS1ACBE were more expensive and less effective than colonoscopy.
RESULTS OF SENSITIVITY ANALYSES: The cost of colonoscopy was
reduced to $1,686 per QALY when age at entry was changed to 45.
Watchful waiting became the least expensive strategy when community
procedure charges replaced Medicare costs, when age at entry was
maximized to 80, or when the prevalence of polyps was lowered to 7%,
but the remaining strategies provided greater life expectancy at relatively low cost. The strategy of FS1ACBE remained more expensive and
less effective in all analyses. In the remaining sensitivity analyses, the
incremental cost-effectiveness of colonoscopy compared with flexible
sigmoidoscopy never rose above $34,000.
CONCLUSIONS: Colonoscopy is a cost-effective method to evaluate
otherwise asymptomatic rectal bleeding, with a low cost per QALY
compared to other strategies.
KEY WORDS: rectal bleeding; hematochezia; cost-effectiveness analysis; diagnosis; colorectal cancer.
DOI: 10.1111/j.1525-1497.2005.40077.x
J GEN INTERN MED 2005; 20:81–90.

R

ectal bleeding is a common symptom, with a prevalence
of 14% to 19% in adults.1–4 Most patients bleed from
benign sources such as hemorrhoids and diverticula, but
others have serious colorectal disease including colon cancer,
adenomatous polyps, and inflammatory bowel disease (IBD).
Accepted for publication July 1, 2004
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Colon cancer is the third leading cause of cancer-related
death in this country.5 The majority of medical societies
recommend some form of colon cancer screening for asymptomatic adult patients over age 50. The evaluation of rectal
bleeding is different from screening because the risk of serious
disease is higher and it is unclear whether early diagnosis and
treatment of serious disease results in improved mortality
once gross bleeding has occurred.
The optimal evaluation strategy for rectal bleeding is
unknown. Neither historical information nor the presence or
absence of hemorrhoids has been shown to reliably differentiate benign from serious disease.6–11 Fecal hemoccult testing is
not a viable evaluation option for these patients as by definition they have observed blood in or on their stools. Potential
strategies for investigation include watchful waiting, flexible
sigmoidoscopy, flexible sigmoidoscopy followed by air contrast
barium enema, or colonoscopy. Each of these strategies carries with it cost, discomfort, risk for complication, and a
chance for false positive and negative results. Ultimately the
choice of strategy depends on whether or not making an
accurate diagnosis of serious disease will prolong life at an
acceptable cost.
Little is known about the relative cost implications of the
evaluation strategies for patients over the age of 40 with rectal
bleeding. Our objective was to compare the cost-effectiveness
of four commonly employed diagnostic strategies for the evaluation of rectal bleeding.

METHODS
Model Overview
We developed a Markov decision model (Fig. 1) to simulate
the natural history of patients with rectal bleeding. An
explanation of the disease states included in the model
is available in Appendix 1 (available online at http://
www.blackwellpublishing.com/products/journals/suppmat/
jgi40077/jgi40077.htm). The base case consisted of a 55-yearold patient presenting with one or more episodes of rectal
bleeding, defined as blood on toilet paper, in toilet bowl, mixed
in stool, or on stool. Patients with melena were not included.
The time horizon was the patient’s lifetime. The patient was
asymptomatic with no family or personal history of colon
cancer or polyps and no screening within the last 10 years.
We considered four diagnostic strategies: watchful waiting
(WW), flexible sigmoidoscopy (FS), flexible sigmoidoscopy followed by air contrast barium enema (FS1ACBE), and colonoscopy. The model assumed that patients in the WW arm would
only be worked up with colonoscopy if they had recurrent
bleeding after 1 year. Patients in both the FS and FS1ACBE
arms proceeded to colonoscopy if they had positive findings on
FS, ACBE, or an incomplete exam. For FS, an incomplete exam
81
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was defined as visualization of less than 45 cm of the colon.
For ACBE, it was defined as inability of the patient to tolerate
the exam or films of sufficiently poor quality as to preclude
interpretation. Discovery of adenomatous polyps, colorectal
cancer, or IBD constituted a positive exam. In the FS1ACBE
arm a negative FS was followed by an ACBE.

Model Estimates
We conducted a systematic review of the literature to estimate
the prevalence of serious disease in patients with rectal bleeding
and the accuracy of the diagnostic tests being considered
in each of the strategies. The methods used to perform this
review are described in Appendix 2 (available online at http://
www.blackwellpublishing.com/products/journals/suppmat/jgi/
jgi40077/jgi40077.htm). Appendix 3 (available online at
www.jgim.org) details the results of each of these systematic
reviews. When possible, we pooled data using a random-effects
model and based point estimates for the base-case scenario on
these pooled data. In cases where pooling was not possible, we
based point estimates for the base-case scenario on data from
an expert panel review.5 Ranges around point estimates reflect
all values we identified in the literature even if the studies did
not meet inclusion criteria for the systematic review. Table 1
outlines our base-case probability estimates, range around
these estimates, and sources included in the model. We assumed that patients without serious disease had an annual
chance of recurrent rectal bleeding of 5% and underwent
colonoscopy if they had never successfully completed one.
Given uncertainty about rates of recurrent bleeding, we ranged
this percentage from 1% to 30% in the sensitivity analysis.
Patients diagnosed with small adenomatous polyps (polyps o1
cm without villous or high-grade dysplastic features) were
assumed to have a surveillance colonoscopy every 5 years
and those with large adenomatous polyps (  1 cm or with
villous or high-grade dysplastic features) every 3 years. Surveillance continued life long.
We defined serious disease as colorectal cancer, adenomatous polyps of any size, and IBD. We estimated the probability of
serious disease in adult patients over the age of 40 presenting to
their primary care providers with rectal bleeding from 6 prospective studies.6,7,9–12 Patients with anorectal disease such as
hemorrhoids and fissures and those with diverticula were not
considered to have serious disease. Patients could die from
other causes while in any state of the model. The probability
of dying of other causes was based on 1997 life tables.13
Patients remained in the model until age 100 or death.

Natural History
As there is no widely agreed-upon strategy to estimate how
quickly adenomatous polyps progress to invasive cancers, we

FIGURE 1. Overview of model. (A). The Markov decision model
depicts the four diagnostic strategies a patient with rectal bleeding could potentially undergo. (B). Disease states at entry to the
model and progression over time. Patients enter with the undiagnosed version of their disease state and can stay in that state and
be diagnosed at a later date, progress to the next most advanced
disease state and be diagnosed at that time, be diagnosed initially
and appropriately treated, or die from other causes. See Appendix
1 (available online at http://www.blackwellpublishing.com/products/journals/suppmat/jgi/jgi40077/jgi40077.htm).
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assumed that smaller adenomatous polyps would progress to
large polyps in an average of 10 years and that large adenomatous polyps would progress to invasive cancer in an average
of 10 years.5,14–20 We ranged average progression time from 5
to 15 years in the sensitivity analysis. Once invasive cancer
was present we assumed average transition times of 2 years, 1
year, and 1 year between Dukes A, B, C, and D cancers,
respectively, in undiagnosed patients.14–16 Mortality within
each stage of cancer was estimated from the Surveillance,
Epidemiology, and End Results (SEER) cancer registry. We
did not take into account the development of new polyps over
time, and thus we modeled only the effects of the diagnostic
strategies on disease present at the time of initial evaluation.

Diagnostic Strategies
When available, we obtained sensitivity and specificity estimates as well as completion rates for each of the tests based
on a review of prospective diagnostic studies in patients with
rectal bleeding. For ranges around these estimates we used all
information we could find in the literature. In the FS1ACBE
arm, we considered the sensitivity and specificity of FS and
ACBE separately so as to allow a patient with an inadequate or
positive FS to go straight to colonoscopy without first getting an
ACBE. As in other cost-effectiveness analyses,21,22 we assumed
that patients with missed cancers, polyps, or IBD would ultimately become symptomatic, prompting further diagnostic evaluation by colonoscopy. We estimated that 90% of polyps would
be diagnosed within 7 years, and 90% of Dukes A, B, C, and D
cancers by 2, 2, 1, and 1 years, respectively. We estimated that
90% of patients with IBD would be diagnosed within 2 years.

Costs
We adopted a modified societal perspective21 (Lewis 2002) in
that all direct medical costs were considered regardless of who
incurred them. We did not include indirect costs. Costs relating to testing and treatment are outlined in Table 1. Cost
differences between diagnostic strategies result either from
the cost of tests and their complications or from the variation
in treatment costs due to a delay in diagnosis. We did not
consider the cost of other care that may have ensued from
missed or undiagnosed serious disease. In the primary analysis, we estimated procedural costs using the 2001 Medicare fee
schedule to be consistent with recommendations from the
Panel of Cost-effectiveness in Health and Medicine23–25 and
other cost-effectiveness analyses on colon cancer screening.22,26,27 We obtained estimates for the cost of colorectal
cancer treatment from a study using 1990–1994 data from
the SEER-Medicare linked database28 and adjusted them to
2001 dollars using the Medical Care Consumer Price Index
from the U.S. Bureau of Labor and Statistics. We performed an
alternate scenario analysis to reflect charges for procedures
performed in the community setting. These charge estimates
were derived from an average of professional and facility fees
for procedures performed in 3 hospital systems in our own
community. We also performed an alternate scenario analysis
using costs of cancer care in the managed care setting.28–30
Because it is unlikely that patients with early-stage cancers
(Dukes A and B) will incur yearly costs related to their cancer
throughout their lifetime, we performed a sensitivity analysis
in which the cost incurred by these patients was that of
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Table 1. Model Assumptions
Base Case

Causes of rectal bleeding in patients 440 years
Polyp, %
Large (1 cm)
Small (o1 cm)
Colorectal cancer, %
Dukes A
Dukes B
Dukes C
Dukes D
IBD
Location of lesions
Cancers in left colon, %
Polyps in left colon, %
Right-sided lesions with associated left-sided lesions, %
Rate of rebleeding, %
5-year colorectal cancer mortality, %
Dukes A
Dukes B
Dukes C
Dukes D
Diagnostic test characteristics
Sensitivity of FS for, %
Rectosigmoid
cancer
Rectosigmoid
polyp
IBD
Specificity of FS
Sensitivity of ACBE for, %
Cancer
Polyp
IBD
Specificity of ACBE
Sensitivity of colonoscopy for, %
Cancer
Polyp
IBD
Procedure complication rates, %
Colonoscopy: hemorrhage
Colonoscopy: perforation
Colonoscopy: mortality
FS: perforation
FS: mortality
ACBE: perforation
ACBE: mortality
Procedure completion rates, %
FS
ACBE
Colonoscopy
Cost: procedures
FS
ACBE
Colonoscopy
Polypectomy (including pathology)
Costs: cancer care
Dukes A
Initial
Incremental
Dukes B
Initial
Incremental
Dukes C
Initial
Incremental
Dukes D
Initial
Incremental
Terminal
IBD costs

16
30
70
7
47
20
26
7
8
72
78
48
5

Sensitivity Analysis
Range

0.7–25.2
20–50
59–80
0–11.5
8–47
20–46
26–50
0–15
3–16
66–82
66–86
30–80
1–30

11.12
24.25
42.69
93.69

References

(7, 9–12)
(8, 11, 21, 43, 44)
(8, 11, 21, 43, 44)
(7, 9–12)
(9–11)
(9–11)
(9–11)
(9–11)
(9–12)
(45, 46)
(45, 46)
(45, 46)

(47)
(47)
(47)
(47)

95

85–100

(5, 48–52)

85

75–98

(5, 48, 49, 51–53)

67
96

50–100
92–100

(42, 54)
(5, 10, 50, 51)

83
58
33
93

60–100
27–93
23–43
78–100

(5, 42, 48, 49, 51, 52, 54–71)
(5, 42, 48-55, 61, 68–79)
(42, 54, 71, 72)
(10, 51, 72, 75, 79)

95
96
83

90–100
75–100
83–93

(5, 42, 56–60, 80)
(5, 42, 61, 72, 73, 80, 81)
(42)

0.007
0.004
0.0001
0.001
0.00000006
0.0001
0.00002
75
85
90
$152
$288
$620
$216

0.0024–.046
0.00001–.0214
0.00005–0.0003
0.0001–0.05
0–0.00005
0.00004–0.0002
0.000004–0.00002
65–85
75–95
80–100
$100–$844
$200–$500
$200–$2,200
$150–$500

(82–86)
(5, 44, 83, 87–98)
(5, 92)
(5, 89, 99)
(5, 44, 86, 88, 89, 91, 92)
(5, 100, 101)
(100, 101)
(102)
(44, 89, 93, 103)
2001
2001
2001
2001

Medicare
Medicare
Medicare
Medicare

$19,654
$1,552

$16,680–$31,744
$200–$3,183

(28–30)
(28–30)

$25,601
$1,552

$16,680–$31,744
$200–$3,183

(28–30)
(28–30)

$28,705
$2,845

$19,182–$37,208
$2,020–$4,038

(28–30)
(28–30)

$27,412
$6,724
$19,654
$9,415

$21,921–$39,209
$6,000–$22,042
$17,378–$24,800
$5,740–$12,915

(28–30)
(28–30)
(28–30)
(104)

Physician
Physician
Physician
Physician

Fee
Fee
Fee
Fee

Schedule
Schedule
Schedule
Schedule

(Continued)
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Table 1 (continued )
Base Case

Costs: procedural complications
Perforation
Hemorrhage
Quality of life utilities
Dukes A
Dukes B
Dukes C
Dukes D
Terminal
IBD
Undiagnosed IBD

Sensitivity Analysis
Range

$13,598
$4,561

$10,000–$50,000
$4,000–$8,000

0.74
0.74
0.63
0.27
0.27
0.85
0.65

0.7–0.9
0.59–0.9
0.59–0.84
0.24–0.84
0.24–0.65
0.55–0.9
0.55–0.75

References

(22, 27, 32, 44)
(27)
(33–35)
(33–35)
(33–35)
(33–35)
(33–35)
(35, 105)

IBD, inflammatory bowel disease; FS, flexible sigmoidoscopy; ACBE, air contrast barium enema.

surveillance colonoscopy alone. Costs for care of procedural
complications including hemorrhage and perforation were also
estimated from the literature.22,27,31,32 All costs and effects
were discounted at an annual rate of 3%.

Quality of Life
We based quality of life estimates for patients with cancer on
utility valuations derived from a sample of patients who had
previously undergone resection of a colorectal polyp33 (Table
1). The range of utilities includes information derived from a
study in patients who had colorectal cancer and from a review
study assessing quality of life in various disease states.33–35
Quality of life estimates for IBD incorporate values from patients with either ulcerative colitis or Crohn’s disease.35 Utility
data were highly variable based on the populations studied
and methods used to assess quality of life. In the sensitivity
analysis, we ranged values broadly to reflect this uncertainty.

Analysis
We used Data 4.0 (TreeAge Software Incorporated, Williamstown, MA) to perform the cost-effectiveness analysis. We report
results as cost, effectiveness, and incremental cost-effectiveness, defined as the additional cost per quality-adjusted year
of life saved as compared to the alternate strategy (QALY).
Univariate sensitivity analyses were performed on each of
the variables, ranging them through all probability estimates
found in the literature. When insufficient data existed in the
literature we ranged variables widely to include all plausible
values. We performed several types of multivariate analyses.

First, we performed two-way sensitivity analyses on age with
prevalence of polyps and on cost of FS with cost of colonoscopy, as these variables had the greatest impact on the
results of the univariate sensitivity analyses. Second, we conducted 4 alternate scenario analyses: 1) adjusting serious
disease prevalence to that seen in patients aged 40 to 49,36
2) using procedure charges from the community setting, 3)
adjusting treatment costs to those seen in managed care, and
4) adjusting quality of life estimates to those seen in colorectal
cancer survivors (Table 2).

RESULTS
Base-case Analysis
Table 3 shows the results of the base-case 55-year-old patient
with rectal bleeding. The least expensive strategy was FS,
followed by colonoscopy, and then FS1ACBE. The most expensive strategy was WW. Colonoscopy offered the greatest life
expectancy followed by FS1ACBE and then FS alone. The
incremental cost-effectiveness for colonoscopy compared to
FS was $5,480 per QALY. The incremental cost-effectiveness
of FS1ACBE compared to FS alone was $25,107 per QALY.
Watchful waiting and FS1ACBE were dominated by colonoscopy, meaning they were more expensive and offered lower
life expectancy.

Univariate Sensitivity Analyses
Table 4A shows the results of all univariate sensitivity
analyses in which the incremental cost-effectiveness ratio of
colonoscopy exceeded $10,000 compared to FS. High preva-

Table 2. Model Assumptions for Alternate Scenario Analyses
Incidence of serious disease in
patients aged 40–49, %36
Procedure charges in community setting

Cost of cancer care in the managed
care setting30

QOL with cancer based on patients with
colorectal cancer: HUI34

Small Polyps
6.25

Large Polyps
4.3

Cancer
0.4

IBD
8.2

FS
$844

ACBE
$290

Colonoscopy
$2,200

Polypectomy
$500

Dukes A
Initial
$16,680
Incremental
$440

Dukes B
Initial
$16,680
Incremental
$440

Dukes C
Initial
$19,182
Incremental
$2,020

Dukes D
Initial
$21,921
Incremental
$22,041

Terminal
$17,378

Dukes A
0.84

Dukes B
0.86

Dukes C
0.85

Dukes D
0.84

Terminal
0.65

IBD, inflammatory bowel disease; QOL, quality of life; HUI, health utilities index; FS, flexible sigmoidoscopy; ACBE, air contrast barium enema.
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Table 3. Results of Base-case Analysis
Strategy

FS
Colonoscopy
FS1ACBE
Watchful wait
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Cost

Effectiveness
(QALY)

$17.1K
$17.2K
$17.3K
$17.5K

14.876
14.890
14.885
14.665

Table 4A. Results of Univariate Sensitivity Analyses

Incremental
Cost-effectiveness
Compared to FS

$5,480
$25,107
Dominated

Flexible sigmoidoscopy followed by ACBE.

QALY, quality-adjusted year of life saved; FS, flexible sigmoidoscopy;
ACBE, air contrast barium enema.

lence of IBD and prolonged time to diagnosis of this disease
raised the incremental cost-effectiveness ratio of colonoscopy,
as did a high sensitivity of FS for polyps, a low sensitivity of FS
for IBD, and maximal rates of perforation and hemorrhage
during colonoscopy.
Table 4b shows the results from all univariate sensitivity
analyses in which the dominance pattern changed and FS was
no longer the cheapest option. As age at entry increased, the
effectiveness of all invasive strategies began to decrease. By
age 78, WW became the least costly strategy (referent) even
though other strategies were still associated with a longer life
expectancy. Flexible sigmoidoscopy cost an additional $987
per QALY compared to WW. At this older age, colonoscopy
became considerably less cost-effective, with an incremental
cost-effectiveness of $35,000 per QALY relative to FS. When
the prevalence of polyps was minimized to less than 10%, WW
once again became the cheapest strategy, with FS offering an
incremental cost-effectiveness of $1,876 per QALY and colonoscopy an additional $15,168 compared to FS. When polyp
prevalence was maximized, FS returned to being the cheapest
strategy and the incremental cost per QALY for colonoscopy
came down to $980 compared to FS. Finally, when the cost of
colonoscopy was minimized to $200, this became the cheapest
and most effective strategy dominating all others. At maximal
colonoscopy cost, FS returned to being the cheapest option.
The incremental cost-effectiveness as compared to FS was
$35,953 for FS1ACBE and $33,955 for colonoscopy. Finally,
when the cost of FS was maximized, colonoscopy became the
cheapest and most effective strategy dominating all others.
Univariate sensitivity analyses of the variables not shown did
not significantly alter the results.

Multivariate Analyses
Two-way Sensitivity Analysis. Figure 2 shows the results of an
analysis varying both age at entry and prevalence of polyps.
The greatest predictor of cost per effectiveness was age. As age
increased, the cost per effectiveness of all strategies increased.
At any age, the prevalence of polyps had the greatest effect on
WW. Except for the youngest cohort, FS was always more costeffective than colonoscopy. The difference between FS and
colonoscopy decreased with increasing polyp prevalence and
increased with age. In the older cohorts, WW became the most
cost-effective strategy at lower polyp prevalence, but this was
only the case when the prevalence of polyps was less than 12%
at age 75 and less than 8% at age 65. In the youngest cohort,
the cost-effectiveness of colonoscopy and FS are almost identical and are always better than WW. A two-way sensitivity
analysis varying the cost of colonoscopy and FS produced

Variable

Range

Base case

Incremental
Cost-effectiveness
of Colonoscopy
Compared to FS
$5,480

Prevalence of IBD

2.2%
20%
0.5 years
3.5 years
0.001%
2.14%
0.24%
4.6%
25%
80%
75%
98%

Time at which 90% IBD
cases diagnosed
Risk for perforation with
colonoscopy
Risk for hemorrhage with
colonoscopy
Sensitivity of FS for IBD
Sensitivity of FS for
rectosigmoid polyp

$2,738
$10,097
$1,057
$10,021
$3,229
$15,296
$4,609
$12,860
$11,263
$3,415
$2,840
$10,369

FS, flexible sigmoidoscopy; IBD, inflammatory bowel disease.

Table 4B. Results of Univariate Sensitivity Analyses
Variable

Range

Incremental Cost-effectiveness Ratio
WW

Base case
Age at entry

Dominated
40 years Dominated
80 years Referent
Prevalence of
7%
Referent
polyps
27%
Dominated
Cost of colo
$200
Dominated
$2,200 Dominated
Cost of FS
$100
Dominated
$844
Dominated

FS

FS1ACBE

Colo

Referent
Dominated
$987
$1,876
Referent
Dominated
Referent
Referent
Dominated

Dominated
Dominated
Dominated
Dominated
Dominated
Dominated
$35,954
Dominated
Dominated

$5,480
Referent
$35,532
$15,168
$980
Referent
$33,955
$9360
Referent

WW, watchful waiting; FS, flexible sigmoidoscopy; FS1ACBE, flexible
sigmoidoscopy followed by air contrast barium enema; colo, colonoscopy.

results that were relatively similar to those discussed in the
univariate analyses.
Alternate Scenarios. In the analysis using disease prevalence
data from patients aged 40 to 49 (Table 5A), the incremental
cost-effectiveness of colonoscopy decreased to $1,686 per
QALY compared to FS. In the analysis using procedure charges
in the community setting (Table 5B), WW became the cheapest
strategy followed by colonoscopy. Colonoscopy remained the
most effective strategy. Both FS and FS1ACBE were dominated in this scenario. The incremental cost-effectiveness for
colonoscopy compared to WW was $1,246 per QALY. Secondary analyses using cost data from the Group Health Healthcare
system (Table 5C) and adjustment of quality of life data to
reflect estimates obtained from cancer survivors did not significantly alter the results.

DISCUSSION
We compared four commonly used diagnostic strategies for the
evaluation of patients aged 40–80 with rectal bleeding. We
found FS to be the cheapest test and colonoscopy to be the

JGIM

Table 5. Results of Alternate Scenario Analyses
A. Base-case Age 45

1450

Strategy

Cost

Effectiveness
(QALY)

Incremental
C/E

$19.2K
$19.2K
$19.4K
$19.5K

18.990
19.004
18.999
18.881

$1,686
Dominated
Dominated

1400

Age 75
1350

colo age 45
colo age 55
colo age 65
colo age 75
ww age 45
ww age 55
ww age 65
ww age 75
fs age 45
fs age 55
fs age 65
fs age 75
fs/acbe age 45
fs/acbe age 55
fs/acbe age 65
fs/acbe age 75

1300
Cost per effectiveness
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1250
Age 65
1200

1150
Age 55

FS
Colonoscopy
FS1ACBE
Watchful wait

B. Procedure Charges in the Community Setting
Strategy
Watchful wait
Colonoscopy
FS
FS1ACBE

Cost

Effectiveness

19.7K
19.9K
20.2K
20.5K

14.665
14.890
14.876
14.885

Incremental C/E

$1,246
Dominated
Dominated

C. Group Health Treatment Cost
Strategy
FS
Colonoscopy
FS1ACBE
Watchful wait

Cost

Effectiveness

$16.1K
$16.1K
$16.3K
$16.3K

14.876
14.890
14.885
14.665

Incremental C/E

$5,421
Dominated
Dominated

QALY, quality-adjusted year of life saved; C/E, cost-effectiveness;
FS1ACBE, flexible sigmoidoscopy followed by air contrast barium
enema.

1100
Age 45

1050
0.07

0.1155

0.161

0.2065

0.252

Prevalence of polyps

FIGURE 2. Two-way sensitivity analysis varying prevalence of polyps
and age at entry. The y axis represents cost per effectiveness and
the x axis represents prevalence of polyps. Separate analyses are
shown for cohorts starting at ages 45, 55, 65, and 75. Results for the
age 45 cohort are marked with X, age 55 with triangles, age 65
with squares, and age 75 with circles. The strategy of colonoscopy
is depicted by a solid line, flexible sigmoidoscopy by a shaded line,
flexible sigmoidoscopy followed by air contrast barium enema by
a dotted line, and watchful waiting by a dashed line.

most effective initial test with a relatively low cost per additional year of life saved compared to FS. We found FS followed
by ACBE to be both more expensive and less effective than
colonoscopy.
There is currently no set standard of care for the evaluation of rectal bleeding. Though practice patterns have not been
formally studied, our perception is that clinicians are often
influenced by patient history and examination findings and
thus employ a WW strategy in selected patients. Similarly, there
appear to be significant practice variations in the use of FS,
ACBE, and colonoscopy. One may use the argument that
because screening with colonoscopy is cost-effective22,26,27,37–39
it should remain so in patients presenting with rectal bleeding.
However, uncertainty remains on which evaluation strategy is
most cost-effective in screening patients,40 and the latest
report from the U.S. Preventive Services Task Force suggests
there is insufficient evidence to recommend one strategy over
another.41 Our analysis demonstrates initial colonoscopy has
a very low incremental cost per QALY compared to FS. Additionally, the strategy of WW is both more costly and less

effective than an initial invasive strategy, except in elderly
patients with very low prevalence of polyps.
Our study revealed an unexpected finding that lowering
the age of subjects entering the analysis to 40–49 while
simultaneously lowering serious disease rates to those seen
in this age group made colonoscopy appear even more costeffective than in older patients. We had anticipated that lower
rates of serious disease in younger patients would increase the
incremental cost-effectiveness ratio for colonoscopy. However,
as is demonstrated in the two-way sensitivity analysis of age
and polyp prevalence, age at entry has a much greater impact
on the cost-effectiveness of all strategies than does polyp
prevalence, presumably due to a greater potential for years of
life saved in patients with a greater life expectancy. As age
decreases, the incremental cost of colonoscopy compared to FS
decreases. As polyp prevalence decreases the incremental cost
of colonoscopy compared to FS increases but to a lesser
degree. Thus, in our alternate scenario representing the cohort
of patients aged 40–49, colonoscopy is even more cost-effective
than in our base-case scenario. As full colonoscopic evaluation
is not routinely recommended to patients with rectal bleeding
in this younger age group, this finding has potential policy
implications.
A recent cost-effectiveness analysis of younger patients
with rectal bleeding also found that as patients approached
the age of 40, full colonic evaluation became more cost-effective, but in that analysis FS1ACBE was less expensive and
more effective than colonoscopy.21 In this study, Lewis et al.
found the incremental cost of colonoscopy relative to FS for a
45-year-old patient was $9,360 per year of life gained as
opposed to $3,858 when comparing FS1ACBE to FS alone.
The reasons for this disparity are unclear. In all our analyses,
we found colonoscopy to be associated with a longer life
expectancy than FS1ACBE, whereas the Lewis study found
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the reverse. Because in both studies colonoscopy is more
sensitive than FS or ACBE and the risk of death from colonoscopy is extremely low, one would intuitively expect that
colonoscopy results in longer life expectancy. Regardless, in
both studies full colonic evaluation is favored, and the incremental cost-effectiveness of colonoscopy compared to FS remains under $10,000.
Another interesting finding was the change in dominance
patterns when using community procedure charge data in
place of Medicare procedure cost data. In this scenario, WW
became the cheapest strategy, with an incremental cost per
QALY for colonoscopy compared to WW of only $1,246. While
the procedural cost for colonoscopy increased by a greater
absolute dollar amount than it did for FS, it was a proportionally smaller increase. As a result, the FS and FS1ACBE
strategies became much more expensive and were dominated
by the colonoscopy strategy. Of note, all strategies in this
scenario were considerably more expensive than in the basecase scenario. It is the difference between strategies that
decreased, not the overall cost per effectiveness in absolute
terms.
We believe the results favoring colonoscopy are robust. We
made several assumptions that biased the results against
colonoscopy. We assumed very low rebleeding rates in patients
without serious disease, thus minimizing the number of unnecessary colonoscopies in the WW, FS, and FS1ACBE arms.
Also, patients found to have polyps were placed in a surveillance state indefinitely where they continued to accrue the cost
and risks of repeated colonoscopies without any benefit because we did not model the appearance of new lesions over
time. This assumption biases against colonoscopy because
this strategy is most likely to put patients in the surveillance
state for the longest period of time. Additionally, we did not
account for the cost of increased physician visits that would
result from undetected disease. As we would expect more
missed disease in the strategies that do not begin with colonoscopy, colonoscopy benefits the least from this omission.
Finally, we considered the sensitivity and specificity of FS
and ACBE separately so as to allow patients with a positive
FS to go to colonoscopy without getting an ACBE first. In our
model, if both ACBE and FS are successfully completed, the
sensitivity for polyps of the tests performed in series is 90%.
This estimate is higher than what has been found in studies
that assessed the sensitivity of the combined strategy.10,42
Improved sensitivity for polyps would likely make the
FS1ACBE strategy appear more effective than it actually is.
This study has several limitations. First, while we systematically sought the best available evidence, we had no reliable
information on the natural progression of disease, rebleeding
rates, and time to diagnosis of missed disease. To compensate,
we ranged our estimates very broadly across all values that
seemed plausible. The sensitivity analysis demonstrated that
there was no appreciable change in our basic conclusion even
at the extremes of the estimates. Second, we did not include
indirect costs of procedures and cancer care, which may have
biased the model in favor of colonoscopy. Third, it is unlikely
that a physician in practice would relegate all adult patients
presenting with rectal bleeding into a WW strategy. Rather,
based on history, physical, and anoscopy findings, the decision to pursue invasive work-up would be made for some
patients and not for others. A more accurate reflection of this
process would be a strategy in which those patients found to
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have hemorrhoids or fissures on anoscopy were treated with
conservative measures and only evaluated invasively if symptoms persisted. Those without findings on anoscopy would go
on to immediate work-up. However, there is a considerable
body of information suggesting that historical information and
results of anoscopy correlate poorly with actual findings at
colonoscopy.6–11 A patient referred for invasive evaluation
based on initial clinical findings is no more or less likely to
have disease than one who lacks clinical findings. Thus,
distribution of patients into an early work-up versus workup based on symptoms or anoscopy results would put equal
numbers of diseased patients into each arm, mirroring what
already occurs in the model.
Despite these limitations, our study has several important
implications. All patients over the age of 40 presenting with
rectal bleeding should have at least a partial evaluation of the
colon. Colonoscopy offers additional prolongation of life at
relatively low cost. These recommendations are even stronger
in patients aged 40–49 as they have the most to lose from
missed diagnoses. While patients at the upper end of the age
spectrum have less benefit from evaluation of the entire colon,
the cost per QALY is still lower than many other interventions
commonly performed in this age group. In situations where
colonoscopy is not readily available, FS followed by ACBE
provides very similar prolongation of life expectancy at a
slightly higher cost. Until the time when we have data from
prospective clinical trials comparing the costs and effects of
these strategies in patients with rectal bleeding, our costeffectiveness model allows clinicians and health care payors
to feel more secure in their choice of an early invasive strategy
to evaluate adult patients with rectal bleeding.
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